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Summary
The paper presents an ontology for the description of Drug Discovery Investigation (DDI).
This has been developed through the use of a Robot Scientist “Eve”, and in consultation
with industry. DDI aims to define the principle entities and the relations in the research
and development phase of the drug discovery pipeline. DDI is highly transferable and ex-
tendable due to its adherence to accepted standards, and compliance with existing ontology
resources. This enables DDI to be integrated with such related ontologies as the Vaccine
Ontology, the Advancing Clinico-Genomic Trials on Cancer Master Ontology, etc.
DDI is available at http://purl.org/ddi/wikipedia or http://purl.org/ddi/home .
1 Introduction
The accumulated historical record of experimental data is one of the most valuable intellectual
property assets of pharmaceutical companies. However, storing experimental data and proto-
cols in sufficient detail to ensure exact reproducibility has proven difficult. The result is that the
extended utility of data or protocols beyond their projects has rarely been demonstrated [1, 2].
The fundamental problem of data exchange and data integration in the pharmaceutical industry
is the lack of formalised agreement on what data and metadata of drug discovery experiment
should be recorded, and how these data should be unambiguously stored. Recently pharma-
ceutical companies have begun to explore the possibility of developing, in a pre-competitive
way, informatics standards to exchange data within the industry and between industry and
academia [3]. In initiatives such as the Pistoia Alliance1, pharmaceutical companies have be-
gun to define a common workflow with a view to standardising processes and terms in the drug
discovery process. In developing these standards the Pistoia Alliance aims to utilise the emer-
gence of semantic based web technologies and service-oriented architectures. This recognition
that the future informatics framework for pharmaceutical research will be based on exchange-
able semantic terms [3] creates the need for an ontological framework for experimental drug
discovery data.
The Harvard Business Review lists the need for a common digital data standard in drug devel-
opment as one of their 10 breakthrough ideas for 2010: “One change would make a substantial
difference: the creation of agreed-upon standards for digitally representing drug assets. The
challenge is that every company has its own idiosyncratic (and therefore redundant) means of
*Correspondence:lss@aber.ac.uk
1 http://pistoiaalliance.sourceforge.net/comms/PistoiaAllianceACSSaltLakeCityMarch2009.pdf
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collecting, storing, and exploiting information from development trials, making it difficult to
share the hundreds of gigabytes of documents and images among partners.” [4]
The use of ontologies is becoming increasingly important in scientific research. One of the
most important applications of ontologies is in the standardisation of the annotation of exper-
iments. Ontology development for experiment annotation in transcriptomics, proteomics, and
metabolomics is well advanced2; although many problems still remain. Biology has led the way
in applying ontologies to science, and the utility of ontologies has been clearly demonstrated in
several biological domains, e.g. Gene Ontology [5], Metabolomics Standards Initiative [6].
Here we propose an ontology for drug discovery investigations (DDI). The purpose of the DDI
ontology is to add value to the information generated in the drug discovery pipeline by making
information generated easier to reuse, integrate, curate, retrieve, and reason with. DDI will also
support information exchange, as companies often have great difficulty exchanging information
on drug discovery (they may be merging, one company is selling the information to the other,
etc.), as their databases/data-standards are typically not comparable. DDI will minimize this
difficulty by providing a standard way for information to be mapped between databases.
1.1 The drug discovery pipeline
Drug discovery is a complex and long-term scientific investigation. It involves a number of
phases that together make up the so called ‘drug discovery and development pipeline’ (Fig-
ure 1). The two main phases are preclinical research, and clinical development. Arguably the
division between these is the first testing of an experimental drug in humans. In essence the
goal of the preclinical research phase is to discover potential drug candidates that are suitable
for clinical trials. It involves target discovery and validation, assay development, and lead gen-
eration and optimisation. The goal of the clinical research phase is to understand the safety of
the compound in humans, and to confirm the efficacy of the drug.
Figure 1: Drug discovery pipeline (see [7] for alternative pipeline drawing)
Various drug discovery (preclinical) process pipelines can be constructed depending on the
strategy that is employed [7]. For example, a forward chemical genetics approach starts with
the screening of compounds to identify those which affect a phenotypic assay in a desired
manner. In contrast, a reverse chemical genetics approach begins with a molecular target of
interest and attempts to discover compounds which modulate that target in a desired way. The
standard pipeline process model of drug discovery normally now assumes a reverse chemical
genetic approach at its core.
2 http://obi-ontology.org
Journal of Integrative Bioinformatics, 7(3):126, 2010 http://journal.imbio.de
doi:10.2390/biecoll-jib-2010-126 2
DDI aims to support recording of data and metadata for the research and development phase
and to be combined with formalisms supporting other phases of the drug discovery pipeline.
1.2 Robot Scientists
A Robot Scientist is a physically implemented computer/robotic system that utilises techniques
from artificial intelligence (AI) to execute cycles of scientific experimentation [8]. A Robot
Scientist is designed to automatically: originate hypotheses to explain observations, devise
experiments to test these hypotheses, physically run the experiments using laboratory robotics,
interpret the results, and then repeat the cycle. Robot Scientists have the potential to increase
significantly the speed and effectiveness of the scientific discovery process and so reduce its
cost [9]. Our Robot Scientist “Adam” is the first to demonstrate the automated discovery of
novel scientific knowledge [8].
Our new Robot Scientist “Eve” is “a prototype system to demonstrate the automation of closed-
loop learning in drug-screening and design” [10]. Eve’s robotic system is capable of moderately
highthroughput compound screening (greater than 10, 000 compounds per day) and is designed
to be flexible enough such that it can be rapidly re-configured to carry out a number of different
biological assays. It is able to automatically switch from mass screening mode to QSAR learn-
ing. Therefore with Eve there is no need to wait until all compounds in a compound library
are screened to start a QSAR process. DDI has been developed for and being used to support
the recording of data and metadata generated by Eve in explicit semantic form. By the end
of the Eve project, drug discovery data and metadata will be publicly available at our project
website, in the same way how we made available the data and metadata generated by Adam
and semantically annotated with an ontology for LABOratory Robot Scientists (LABORS):
http://www.aber.ac.uk/en/cs/research/cb/projects/robotscientist/
1.3 Existing related ontologies
An ontology is “a concise and unambiguous description of what principle entities are relevant
to an application domain and the relationship between them” [11]. The proposed DDI ontology
is orthogonal to existing ontolgies described below and can be integrated with them.
OBO Foundry (Open Biomedical Ontologies) [12] is an ontology library containing a set of
orthogonal interoperable reference ontologies in the biomedical domain and provides a set of
principles for ontology development3. The Basic Formal Ontology (BFO)4 provides the top-
level classes under which OBO Foundry ontologies should build, while the Relation Ontology
(RO) [13] provides the relations that should be used. The use of the same top level classes and
relations guarantees a full compatibility and interoperability within OBO and supports cross-
domain quires and reasoning.
Ontology for Biomedical Investigations (OBI)5 is an integrated ontology for the description
of investigations in the area of biology and medicine. OBI is developed through collaborations
3 http://www.obofoundry.org/crit.shtml
4 http://www.ifomis.org/bfo
5 http://obi-ontology.org
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among 19 biomedical communities (i.e. metabolomics, proteomics, toxilogy, etc.), and is a can-
didate ontology for the OBO Foundry. The Robot Scientist projects joined the OBI Consortium
in 2008. The DDI ontology is an application of OBI for the area of drug discovery. DDI is built
on our previous work EXPO (a generic ontology of experiments) [14] and LABORS [8]. DDI
also uses ontology of information artifacts (IAO)6, which is a spin-off the OBI project, for the
description of information content entities and Phenotypic Quality Ontology (PATO)7 for the
description of qualities.
There are several other related projects. Infectious Disease Ontology (IDO)8 aims to define
entities relevant to both biomedical and clinical aspects of infectious diseases generally. Sub-
domain specific extensions of the core IDO complete the set providing ontology coverage of
entities relevant to specific sub-domains of the infectious disease field, such as specific diseases
or specific areas of research. To ensure consistent representation of vaccine knowledge and to
support automated reasoning, a community-based effort to develop the Vaccine Ontology (VO)
has been initiated9. The intention of the Advancing Clinico-Genomic Trials on Cancer (ACGT)
Master Ontology (MO)10 is to represent the domain of cancer research and management in a
computationally tractable manner. The Ontology of Clinical Research (OCRe)11 is a formal
ontology for describing human studies.
The rest of the paper is organised as follows: section 2 provides a description of the design
principles and key entities of the proposed DDI ontology, section 3 demonstrates applications
of DDI. In section 4, conclusions are made and future works are planned.
2 An ontology for the description of drug discovery investiga-
tions
DDI aims to define the principle entities and the relations in the research and development phase
of the drug discovery pipeline. DDI is designed to be highly transferable and extendable due
to its adherence to accepted standards and compliance with existing ontology resources. This
enables the integration of DDI with such related ontologies as VO, ACGT, etc. These features
of DDI enable it to be developed to cover the whole drug discovery pipeline.
In developing DDI we followed the OBO Foundry principles. We employed BFO, IAO and
OBI to define the top level classes and we used relations defined in RO, IAO and OBI. We
developed DDI as an application of OBI for drug discovery by extending the corresponding
classes. DDI imports terms from Chemical Entities of Biological Interest (ChEBI) [15], e.g.
chebi:molecular entity. DDI follows the Minimal Information to Reference External Ontology
Terms (MIREOT) [16]. DDI is expressed in a W3C standard Web Ontology Language OWL-
DL12. DDI includes the following main branches (shown in Figure 2):
The class ddi:chemical entity describes the principle molecular entities, its parts and chemical
6 http://code.google.com/p/information-artifact-ontology/
7 http://obofoundry.org/wiki/index.php/PATO:Main Page
8 http://www.infectiousdiseaseontology.org/Home.html
9 http://www.violinet.org/vaccineontology/
10 http://www.ifomis.org/wiki/ACGT Master Ontology %28MO%29
11 http://rctbank.ucsf.edu/home/ocre.html
12 http://www.w3.org/TR/owl-features/
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Figure 2: DDI structure
solutions in drug screening and discovery investigations in generic terms. The class ddi:chemical
entity is a subclass of the class obi:material entity which subsumes object, object part, and ob-
ject aggregate. It additionally defines classes relevant to drug design. For example, the class
ddi:small molecule (a monomer with weight under 800 Daltons), ddi:functional group (a part
of a molecule responsible for the characteristic of chemical reactions of such molecule).
The class bfo:processual entity describes processes and processes aggregates. The phases in
drug discovery pipeline are defined as subclasses of the class obi:planed process, e.g. ddi:assay
development phase; ddi:hit confirmation phase. The classes ddi:drug discovery pipeline, ddi:re-
search development phase are modelled as bfo:processes aggregate. Chemical reactions and
interactions are subclasses of the class bfo:process. DDI applies a five-level approach to de-
scribe a specific investigation, which are top to bottom: investigation, study, trial, assay, and
replicate, which are modelled as subclasses of the class bfo:process (see section 3.1 for more
detail).
The class bfo:quality contains the entities which describe the characteristics of material entities,
such as chemical entities, equipment. DDI defines such qualities as ddi:compound quality,
ddi:compound origin (natural or synthetic), ddi:drugability (the likelihood of being able to
modulate a target with a small-molecule drug), ddi:compound library quality (e.g. diversity).
DDI also imports terms form PATO. For example, pato:length, pato:depth, pato:width for the
description of equipment; pato:odor, pato:solubility for the description of chemical entities.
The classes ddi:equipment (a material entity that is manufactured by an organisation or person,
designed with the intent to perform a specific function or functions) and ddi:equipment part
are subclasses of the class obi:processed material (a material entity that is created or changed
during material processing). DDI extends OBI for the description of equipment and equipment
parts used by the Computational Biology laboratory at Aberystwyth University, e.g. ddi:robot,
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ddi:robot arm, ddi:air compressor, ddi:barcode reader. These classes define generic equip-
ment; a specific equipment can be added as an instance of the corresponding class. For exam-
ple, Eve uses three different types of liquid handler to conduct its trials. They are instances of
the class obi:liquid handler. DDI can be easily extended by adding new classes for equipment
which is used in other drug screening and discovery laboratories or companies.
The class bfo:role for the description of role entities which must be played by some material
entity in certain context. For instance, ddi:compound role and obi:drug role are defined as
subclasses of the class bfo:role. A chemical entity plays a compound role in most phases of
drug discovery pipeline, and plays a drug role once it is approved as a drug. This arrangement
allows identity of a material entity to remain unchanged during its lifetime. DDI defines such
essential for drug design roles as ddi:drug target role, ddi:inhibitor, ddi:hit, ddi:lead, etc. and
imports such roles as chebi:agonist, chebi:antagonist.
The class iao:information content entity defines entities that are generically dependent on some
artifact and stands in relation of aboutness to some entity. For example, obi:measurement da-
tum is a subclass of the class iao:information content entity that is the output of an assay.
DDI extends these descriptions by adding the classes ddi:fluorescence polarisation reading,
ddi:optical density reading as specified outputs of mass screening assays run by Eve. The class
obi:plan specification includes parts such as iao:objective specification, iao:action specifica-
tion which are subclasses of iao:information content entity. DDI adds classes ddi:objective
to find hit-set, ddi:objective to find activity (see Figure 3). DDI also defines such information
content entities as ddi:conformation (the spatial arrangement of the atoms affording distinc-
tion between stereoisomers which can be interconverted by rotations about formally single
bonds), ddi:supply format (the format of products provided by a supplier) for the description of
ddi:compound supply format (e.g. powder, liquid).
The DDI assessment against the OBO Foundry principles and other commonly accepted criteria
is summarised in the Table 1.
Table 1: A summary of DDI assessment
Principles DDI assessment against the principles
The ontology must be is a complete. All the DDI classes are connected via is a rela-
tion. There are no “orphan” classes.
The ontology is in a common shared
syntax.
DDI is expressed in W3C standard Web Ontol-
ogy Language OWL-DL.
The ontology includes textual defini-
tions for all terms.
All DDI terms have textual definitions.
The ontology follows an accepted up-
per level ontology.
DDI uses BFO, OBI and IAO as the top ontolo-
gies.
Coverage of the domain DDI aims to provide descriptors for the research
and development phase in the drug discovery
pipeline. Currently DDI covers the drug dis-
covery investigations run by the Computational
Biology Group at Aberystwyth University. We
believe these are typical of the domain.
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The ontology uses relations which are
unambiguously defined following the
pattern of definitions laid down in the
OBO Relation Ontology.
DDI uses relations defined in RO, IAO, and
OBI. The relations defined in IAO and OBI are
candidates for inclusion into RO.
The ontology must be open source. DDI is open and available on its wiki page. It
is designed to be used without any constraint.
However, the original source must be acknowl-
edged and it must not be redistributed using the
same name and the same identifiers.
The otology possesses a unique identi-
fier space within the OBO Foundry.
The prefix ddi is the unique identifier to all DDI
terms.
The ontology provider has procedures
for identifying distinct successive ver-
sions.
DDI is developed under the version control sys-
tem SVN. Changes in DDI were committed to
the SVN repository and were annotated.
The ontology has a clearly specified
and clearly delineated content.
DDI is orthogonal to other ontologies already
lodged within OBO.
The ontology is well documented. DDI is documented in its wiki page for distribu-
tion. More documentation will be provided for
a stage of submission DDI to OBO.
The ontology will be developed col-
laboratively with other OBO Foundry
members.
The DDI team has already started collaboration
with the developers of VO. More OBO Foundry
members will be invited for collaboration on the
next stage of the DDI project.
Multiple inheritance should be dealt
with via defined classes.
In DDI, each class has only one superclass. This
reduces the potential inconsistency and errors in
reasoning processes.
No class can have a single subclass. Each DDI class has either more than one sub-
class or none.
3 Applications
DDI provides a framework for describing the knowledge within drug screening and discovery
domain and for recording the detailed experimental processes.
3.1 The structure of Eve investigations
DDI allows to explicitly and accurately record metadata about investigations, particularly about
a structure of investigations (Figure 3). DDI extends the OBI definition of investigation’s struc-
tural units. OBI aims to describe the most typical investigations in the area of biomedicine
performed by human investigators. The OBI class obi:investigation (a planned process that
consists of parts: planning, study design execution, documentation and which produce con-
clusion(s)) defines a biomedical investigations no matter how small or large it is. The class
obi:assay is used to describe “a planned process with the objective to produce information
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about some evaluant”. The class obi:study design execution is defined as “a planned process
that realizes the concretization of a study design”.
Figure 3: Structure of Eve investigations (blue boxes) and the reuse investigation (red box). The
relations between the structural research units are part of relations.
It is challenging to comprehensively describe investigations with the use of the only three
classes when an investigation has a significantly complex structure. This is especially true for
the automated investigations run by Robot Scientists, where thousands of hypotheses are tested
in parallel, in cycles, and on different levels of granularity [8]. OBI defines investigations and
study design executions in such a way that they cannot have inputs. For example, hypotheses
formed in an obi:hypothesis generating investigation (an investigation in which data is gen-
erated and analyzed with the purpose of generating new hypothesis) cannot be passed to an
obi:hypothesis driven investigation (an investigation with the goal to test one or more hypothe-
sis) (see also the classes expo:hypothesis forming investigation and expo:hypothesis generating
investigation [14]). To overcome these difficulties, DDI defines structural research units on var-
ious levels of granularity. The term obi:investigation is reserved for large investigations where
metadata such as a leading institution, partner institutions, a project, a PI, a funding body, do-
mains (specified by one or more accepted classification systems), general goals and hypotheses,
a time period are recorded. The term ddi:study (a planned process which may consists of parts:
study design execution, trial, assay, trial cycle, replicate and which produces study results and
conclusion(s)) is used for smaller portions of research work performed, where metadata such
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as a domain (one from the list of specified domains for the investigation), an investigator, more
specific hypotheses, time points are recorded, and it can have input information. Studies are
usually parts of a corresponding investigation, and information about a leading institute, fund-
ing etc. can be inferred via part of relations. A study can also be separate from an investigation
research unit. DDI defines the class ddi:trial (a planned process which consists of trial cycles)
to represent cyclic portions of the research performed. Eve analyses the results of each cycle in
order to design and run the next cycle of research. Currently OBI does not support recording
of cyclic research. DDI also defines the class ddi:replicate for assays which use the identical
study design (e.g. a plate layout). Because the investigations are run by robots, it is possible
to accurately repeat assays many times in order to collect required statistics. This approach
allows Eve to detect even minor statistically significant differences in responses which would
be missed by human observation.
The Figure 3 shows a fragment of the investigation into the development of drugs for treatment
of malaria as a part of the investigation into automated novel drug screening and design. The
overall goal of the upper-level investigation is to fully automate drug screening and design. The
developed technology will be applied to the design of drugs targeting 3rd world diseases, e.g.
malaria, and schistosomiasis. Different organisms and different targets will be investigated.
The distinction of investigations on these levels is important. In the investigation into auto-
mated novel drug screening and design Eve plays a role of a subject of the investigation, and
the Computational Biology group at Aberystwyth University is the investigator. We are study-
ing whether a Robot Scientist such as Eve is capable of fully automatic drug design for the
specified diseases and organisms. This investigation is from the domain of AI and Robotics,
and the hypotheses and the conclusions are formed and expressed in terms of that domain. The
investigations into drug screening and design of the selected diseases are run by Eve as the
investigator. It is interesting to note that Eve is designed to run investigations, and therefore an
investigator is not a role for Eve, but a function. This differs from humans who are not designed
to do drug discovery experiments, and for whom an investigator is a role. The recording of the
investigations on different levels allows the expression of such differences and the avoidance of
logical contradictions.
The first part of investigations into a specified disease in a specified organism is a mass screen-
ing study. A compound library is screened in order to find hits – indications of activity of some
compounds. Eve makes a decision to stop screening if the number of hits found is sufficient for
analysis and prediction of activity by a QSAR trial. Within the Robot Scientist project, different
QSAR trials will be run: QSAR-ILP trial, QSAR linear regression trial, QSAR-CoMFA trial,
etc. Each cycle of each QSAR trial consists of a computational QSAR compound activity study
where the specified input from an assay is analysed and predictions about compound activities
are made. The predicted active compounds are not necessarily from the available compound
library. The predicted active compounds could be ordered from other commercial compound
libraries, or specially synthesised. The predicted active compounds are tested at the next phys-
ical quantitative activity assay with many replicates, the results of which are used for the next
QSAR study, and so on until Eve makes the decision that a set of leads is found.
The goal of this “intelligent” approach to screening is enable a significant reduction in the size
of a compound library, and thereby the cost of drug screening experiments. The initial size
of our library is only ∼15, 000 compounds. The definition of structural units of investigations
is important for the efficient analysis and reuse of the collected experimental data. For exam-
ple, the results from different QSAR trials can be easily reused for a new investigation into
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comparison of QSAR algorithms (see Figure 3 red box).
3.2 Mass screening
Figure 4: A fragment of a mass screening study run by Eve.
In this section we describe one blue box “mass screening study” from the Figure 3 on more
detailed level. We employ the same methodology which we used for the description of investi-
gations in LABORS [8] and for modelling the experimental processes in OBI.
During an investigation into development of drugs for a certain disease and for defined targets,
Eve identifies what chimeric yeast strain to use for screening against a compound library. Eve
initiates a ddi:mass screening study which is modelled as an obi:planned process (Figure 4).
The study realizes an obi:plan specification which specifies a ddi:objective to find hit-set and
an obi:study design. The study design consists of a ddi:mass screening protocol, specification
of positive and negative control, and a ddi:plate layout that defines which wells contain yeast
and compounds, and which wells are compounds free.
The mass screening study has part another planned process ddi:mass screening assay which
achieves planned objective to identify activity in the compounds. The assay has such obi:ma-
terial entity as compound which is a bearer of obi:evaluant role and yeast as specified in-
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put, and it outputs optical density and fluorescence polarization reading which are modelled as
obi:data set. These data are analysed by Eve and conclusions about hits are made which are
modelled as obi:study result.
4 Conclusion and future work
DDI proposes a framework for unambiguous and formalised description of drug discovery in-
vestigations. DDI has been developed to support the Robot Scientist Eve which is designed to
run automatic drug discovery investigations. In the development of the proposed ontology, we
have followed OBO Foundry principles and therefore DDI is fully compliant with OBO for-
malisms and can be easily integrated with other existing ontology resources. DDI is designed
in such a way that it can be extended to support the full pipeline of drug discovery.
In the next stage of the DDI project we will collaborate with a number of research groups
(e.g. the developers of VO) in order to extend and to integrate DDI with external resources so
that it can support cross disciplinary queries. We plan to submit DDI to the OBO Portal. The
adoption of DDI will improve the retrieval of past drug discovery investigations, and promote
secondary data reuse. DDI supports ontology-oriented databases which are more flexible than
relational ones. The use of DDI will also improve data curation and maintenance. Use of DDI
will promote semantic web applications that improve lab automation, such as automatically
recording experimental data in e-Lab notebooks. In conclusion, use of DDI will add value to
the data and methods used by pharmaceutical companies, and improve the efficiency of drug
discovery process.
Acknowledgements
This work is supported by BBSRC grant BB/E018025/1, BB/FOF/PF/13/09 and RC UK. We
would like to thank Dr Wilma Keighley, Life Science Consulting, UK and Dr James Ronald
Hudson, Technology Transfer Manager at Aberystwyth University, Wales for consultancy on
the DDI project. We thank Dr Andrew Sparkes at Aberystwyth University, Wales for his con-
tribution to the database development.
References
[1] Gaia V. Paolini, Richard H. B. Shapland, Willem P. van Hoorn, Jonathan S. Mason, and
Andrew L. Hopkins. Global mapping of pharmacological space. Nature Biotechnology,
24(7):805–815, July 2006.
[2] Jason D. Hughes, Julian Blagg, David A. Price, Simon Bailey, Gary A. DeCrescenzo,
Rajesh V. Devraj, Edmund Ellsworth, Yvette M. Fobian, Michael E. Gibbs, Richard W.
Gilles, Nigel Greene, Enoch Huang, Teresa Krieger-Burkee, Jens Loesel, Travis Wager,
Larry Whiteley, and Yao Zhang. Physiochemical drug properties associated with in vivo
toxicological outcomes. Bioorganic & Medicinal Chemistry Letters, 18(17):4872–4875,
September 2008.
Journal of Integrative Bioinformatics, 7(3):126, 2010 http://journal.imbio.de
doi:10.2390/biecoll-jib-2010-126 11
[3] Michael R. Barnes, Lee Harland, Steven M. Foord, Matthew D. Hall, Ian Dix, Scott
Thomas, Bryn I. Williams-Jones, and Cory R. Brouwer. Lowering industry firewalls: pre-
competitive informatics initiatives in drug discovery. Nature Reviews Drug Discovery, 8
(9):701–708, July 2009.
[4] Eric Bonabeau, Alpheus Bingham, and Aaron Schacht. Getting the Drugs We Need.
Harvard Business Review, pages 48–50, January–February 2010.
[5] The Gene Ontology Consortium. Gene Ontology: tool for the unification of biology.
Nature Genet., 25:25–29, 2000.
[6] Susanna-Assunta Sansone, Daniel Schober, Helen Atherton, Oliver Fiehn, Helen Jenk-
ins, Philippe Rocca-Serra, Denis Rubtsov, Irena Spasic, Larisa Soldatova, Chris Taylor,
Andy Tseng, Mark Viant, and Ontology Working Group Members. Metabolomics stan-
dards initiative: ontology working group work in progress. Metabolomics, 3(3):249–256,
September 2007.
[7] Christopher Lipinski and Andrew Hopkins. Navigating chemical space for biology and
medicine. Nature, 432(7019):855–861, December 2004.
[8] Ross D. King, Jem Rowland, Stephen G. Oliver, Michael Young, Wayne Aubrey, Emma
Byrne, Maria Liakata, Magdalena Markham, Pinar Pir, Larisa N. Soldatova, Andrew
Sparkes, Kenneth E. Whelan, and Amanda Clare. The Automation of Science. Science,
324(5923):85–89, April 2009.
[9] Ross D. King, Kenneth E. Whelan, Ffion M. Jones, Philip G. K. Reiser, Christopher H.
Bryant, Stephen H. Muggleton, Douglas B. Kell, and Stephen G. Oliver. Functional ge-
nomic hypothesis generation and experimentation by a robot scientist. Nature, 427(6971):
247–252, January 2004.
[10] Andrew Sparkes, Wayne Aubrey, Emma Byrne, Amanda Clare, Muhammed Khan,
Maria Liakata, Magdalena Markham, Jem Rowland, Larisa Soldatova, Kenneth Whe-
lan, Michael Young, and Ross King. Towards Robot Scientists for autonomous scientific
discovery. Automated Experimentation, 2(1):11, 2010. ISSN 1759-4499.
[11] Steffen Schulze-Kremer. Ontologies for Molecular Biology. In Proceedings of the 3rd
Pacific Symposium on Biocomputing, pages 693–704, 1998.
[12] Barry Smith, Michael Ashburner, Cornelius Rosse, Jonathan Bard, William Bug, Werner
Ceusters, Louis J Goldberg, Karen Eilbeck, Amelia Ireland, Christopher J Mungall, The
OBI Consortium, Neocles Leontis, Philippe Rocca-Serra, Alan Ruttenberg, Susanna-
Assunta Sansone, Richard H Scheuermann, Nigam Shah, Patricia L Whetzel, and Suzanna
Lewis. The OBO Foundry: coordinated evolution of ontologies to support biomedical data
integration. Nature Biotechnology, 25:1251–1255, November 2007.
[13] Barry Smith, Werner Ceusters, Bert Klagges, Jacob Ko¨ler, Anand Kumar, Jane Lomax,
Chris Mungall, Fabian Neuhaus, Alan L Rector, and Cornelius Rosse. Relations in
biomedical ontologies. Genome Biology, 6(R46), April 2005.
[14] Larisa N. Soldatova and Ross D. King. An ontology of scientific experiments. J. R. Soc.
Interface, 3(11):795–803, 2006.
Journal of Integrative Bioinformatics, 7(3):126, 2010 http://journal.imbio.de
doi:10.2390/biecoll-jib-2010-126 12
[15] Paula de Matos, Rafael Alcantara, Adriano Dekker, Marcus Ennis, Janna Hastings, Ken-
neth Haug, Inmaculada Spiteri, Steve Turner, and Christoph Steinbeck. Chemical Entities
of Biological Interest: an update. Nucl. Acids Res., page gkp886, 2009.
[16] Me´lanie Courtot, Frank Gibson, Allyson L. Lister, James Malone, Daniel Schober,
Ryan R. Brinkman, and Alan Ruttenberg. MIREOT: The Minimum Information to Ref-
erence an External Ontology Term. In ICBO: International Conference on Biomedical
Ontology, 2009.
Journal of Integrative Bioinformatics, 7(3):126, 2010 http://journal.imbio.de
doi:10.2390/biecoll-jib-2010-126 13
